Press Releases

VALENCIA, Calif., Sept 20, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the UBS 2005 Global Life Sciences Conference to be held September 26-29, 2005 at the Grand Hyatt Hotel in New York.

Management is scheduled to speak on Tuesday, September 27, 2005 at 4:00 p.m. Eastern Time (1:00 p.m. PDT) to provide an update on the Company.

Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company's website at www.mannkindcorp.com. A replay of the presentation will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the U.S. and Europe to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit www.mannkindcorp.com.

SOURCE:
MannKind Corporation

Dick Anderson, Chief Financial Officer of MannKind Corporation, +1-661-775-5302, danderson@mannkindcorp.com; or Investor Relations, Julie Huang of Financial Dynamics, +1-212-850-5628, Julie.Huang@fd.com, for MannKind Corporation

http://www.prnewswire.com